文献速递临床微生物质量管理与危急值

抗菌药物谱新进展:CLSI M39指南更新与当前趋势

What's New in Antibiograms? Updating CLSI M39 Guidance with Current Trends.
PubMed 文献 · J Clin Microbiol · 2022-08-02

本文综述了CLSI M39指南第5版对累积药敏试验数据分析和抗菌药物谱报告的最新建议。指南考虑了药敏试验与报告推荐的变化及先进信息学技术的引入,并扩展了抗菌药物管理项目对抗菌药物谱的应用。文章回顾基本建议并提供增强报告的新建议。

要点

  • 累积药敏数据可用于制备医疗机构级抗菌药物谱,指导经验性治疗。
  • CLSI M39第5版纳入药敏试验变化与信息学技术,更新分析和呈现建议。
  • 抗菌药物管理项目对抗菌药物谱的使用已扩展,指南予以关注。

核心结论

  • CLSI M39第5版更新了累积药敏数据分析和抗菌药物谱报告的建议,以适应药敏试验变化、信息学技术及抗菌药物管理项目扩展的需求。

研究设计与样本

  • 本文为小综述,回顾CLSI M39指南自2000年首版以来的变化,并介绍第5版更新内容。

主要发现

  • 累积药敏数据可在地方、区域、国家和全球层面汇总,用于估计敏感率、记录趋势和识别耐药威胁。
  • CLSI M39第5版考虑了药敏试验和报告推荐的变化以及先进信息学技术的引入。
  • 抗菌药物管理项目对抗菌药物谱的使用已显著扩展,指南中已涉及。

临床怎么用

  • 临床微生物实验室可依据CLSI M39第5版分析和呈现累积药敏数据,生成抗菌药物谱以支持经验性治疗和抗菌药物管理。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

A vast amount of antimicrobial susceptibility test (AST) data is generated from routine testing in diagnostic laboratories for the primary purpose of guiding clinicians in antimicrobial therapy decisions for their patients. However, there is additional value for these data when they are compiled at the local, regional, national, and global levels. Cumulative AST data can be used to prepare antibiograms at the individual health care facility level. These reports can be used to gain insight into appropriate empirical therapy options prior to the availability of AST results on an individual patient's isolate. Different types of cumulative AST data reports can also be compiled at the regional, national, and global levels to estimate susceptibility rates in geographic regions, document trends in evolving microbial populations, and recognize the appearance and spread of emerging antimicrobial resistance threats. The first CLSI M39 Guideline for Analysis and Presentation of Cumulative AST Data was published in 2000. Since that time, there have been changes to AST and reporting recommendations as well as the introduction of advanced informatics technologies to analyze and present data. The 5th edition of M39 has taken into consideration these changes to assist those who analyze, present, and utilize routine antibiograms and other types of cumulative AST data reports as well as those who design information systems for the capturing and analyzing of AST data. Furthermore, antimicrobial stewardship programs (ASPs) have expanded considerably, and uses of the antibiogram by ASPs have been addressed. This minireview will remind users of the basic recommendations for analysis and presentation of antibiograms and provide new suggestions to enhance these reports.

来源:J Clin Microbiol,查看原文。版权归原作者所有。

引用

  1. Simner PJ, Hindler JA, Bhowmick T, et al. What's New in Antibiograms? Updating CLSI M39 Guidance with Current Trends. J Clin Microbiol. 2022. PMID: 35916520. doi:10.1128/jcm.02210-21

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。